ACE ImmunoID™: End-to-End Neoantigen Discovery

Neoantigen selection is complex. The ACE ImmunoID Platform, which uses Personalis’ patented ACE Technology, combines augmented exome and transcriptome sequencing with analytics to enable broad tumor immunogenomic characterization. NeoantigenID, a component of the ACE ImmunoID platform, provides you with detailed analytics for comprehensive neoantigen determination.